Literature DB >> 14987575

NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies.

T A McDonagh1, S Holmer, I Raymond, A Luchner, P Hildebrant, H J Dargie.   

Abstract

Many studies have shown that the B-type natriuretic peptides (BNP and NT-proBNP) are proven diagnostic markers for heart failure due to left ventricular systolic dysfunction. The manner in which they are to be used is still being unravelled; most single centre studies have chosen the best concentration of the peptide on ROC analysis as their cut-point resulting in numerous different values for both BNP and NT-proBNP appearing in the literature. We report a different approach of defining an age and sex corrected abnormal concentration for NT-proBNP, derived from normal individuals within a large sample of 3051 subjects pooled from three European epidemiology studies and applying that to the entire population to detect HF and LVD. Three thousand and fifty one subjects were studied. Of these 10% (305) had significant LVD and 3.1% (94) had HF. The median concentrations of NT-proBNP (IQR) in normals, those with LVD and in heart failure subjects were 20 pg/ml (10.30), 117.3 pg/ml (28.145) and 269.6 pg/ml (54.323), P<0.001, respectively. The area under the ROC curve for NT-proBNP for the detection of 'heart failure' was 0.85 and 0.69 for LVD. NT-proBNP was an independent predictor of the presence of HF on multivariate analysis. An abnormal NT-proBNP was defined as being >95th centile for normals, age and sex corrected, and diagnosed HF with a sensitivity of 75% and a negative predictive value of 99%. In an additional analysis in a breathless subgroup of our population, in 30% a raised NT-proBNP concentration could be explained by HF due to LVD, in another 64% the high BNP level was associated with some other structural of functional cardiac abnormality or renal impairment. We were unable to assign a possible cause to the high NT-proBNP values in 5.9% of this breathless subgroup of the population. An abnormal NT-proBNP concentration is an accurate diagnostic test both for the exclusion of HF in the population and in ruling out LVD in breathless subjects. An elevated NT-proBNP merely indicates the presence of 'cardio-renal distress' and should prompt referral for further investigation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14987575     DOI: 10.1016/j.ejheart.2004.01.010

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  39 in total

1.  Association of N-terminal pro-brain natriuretic peptide with cardiac disease, but not with vascular disease, in systemic lupus erythematosus.

Authors:  Diana Goldenberg; Emily Miller; Michelle Perna; Naveed Sattar; Paul Welsh; Mary J Roman; Jane E Salmon
Journal:  Arthritis Rheum       Date:  2012-01

2.  Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes.

Authors:  Alain G Bertoni; Lynne E Wagenknecht; Dalane W Kitzman; Santica M Marcovina; Julia T Rushing; Mark A Espeland
Journal:  Obesity (Silver Spring)       Date:  2011-09-29       Impact factor: 5.002

3.  Autoantibody profiling on a plasmonic nano-gold chip for the early detection of hypertensive heart disease.

Authors:  Xiaoyang Li; Tatiana Kuznetsova; Nicholas Cauwenberghs; Matthew Wheeler; Holden Maecker; Joseph C Wu; Francois Haddad; Hongjie Dai
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

4.  Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.

Authors:  Lisa C Costello-Boerrigter; Guido Boerrigter; Margaret M Redfield; Richard J Rodeheffer; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Denise M Heublein; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2006-01-04       Impact factor: 24.094

5.  Amino-terminal pro-brain natriuretic peptid in prediction of left ventricular ejection fraction.

Authors:  Mugdim Bajrić; Fahir Baraković; Zumreta Kusljugić; Nermin Salkić; Elmir Jahić; Mensura Ascerić; Farid Ljuca; Denis Mrsić; Elnur Smajić; Jasmin Caluk; Ramiz Hajrić
Journal:  Bosn J Basic Med Sci       Date:  2008-08       Impact factor: 3.363

6.  Effect of bosentan therapy on ventricular and atrial function in adults with Eisenmenger syndrome. A prospective, multicenter study using conventional and Speckle tracking echocardiography.

Authors:  Mohamed Y Abd El Rahman; Axel Rentzsch; Philipp Scherber; Siegrun Mebus; Oliver Miera; Günther Balling; Petra Böttler; Karl-Otto Dubowy; Birgit Farahwaschy; Alfred Hager; Joachim Kreuder; Brigitte Peters; Felix Berger; Ingram Schulze-Neick; Hashim Abdul-Khaliq
Journal:  Clin Res Cardiol       Date:  2014-03-30       Impact factor: 5.460

Review 7.  Diagnosis of heart failure in primary care.

Authors:  Cândida Fonseca
Journal:  Heart Fail Rev       Date:  2006-06       Impact factor: 4.214

8.  Cocaine-associated increase of atrial natriuretic peptides: an early predictor of cardiac complications in cocaine users?

Authors:  Alessandro Casartelli; Lisa Dacome; Michela Tessari; Jennifer Pascali; Federica Bortolotti; Maria Teresa Trevisan; Oliviero Bosco; Patrizia Cristofori; Franco Tagliaro
Journal:  Heart Asia       Date:  2014-07-08

9.  [Essential cardiac biomarkers in myocardial infarction and heart failure].

Authors:  M Mueller; E Giannitsis; H A Katus
Journal:  Herz       Date:  2014-09       Impact factor: 1.443

Review 10.  Biomarkers in heart failure: a clinical review.

Authors:  J Paul Rocchiccioli; John J V McMurray; Anna F Dominiczak
Journal:  Heart Fail Rev       Date:  2008-12-03       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.